Loading
The labs, companies, foundations, and prizes putting capital behind the field — and what they have shipped so far.
14 of 14 shown
A United States cryonics organization, founded in 1972, that preserves legally dead members at cryogenic temperatures under a trust structure meant to fund storage indefinitely.
A biotechnology company launched in 2022 with about three billion dollars in committed funding to develop cellular rejuvenation programming as a medicine.
An independent research institute in Novato, California, opened in 1999 as the first in the world dedicated solely to the biology of aging.
Alphabet's independent biotechnology company, founded in 2013 to study the biology of aging and develop interventions against age-related disease.
A Texas biotechnology company founded in 2021 to recreate extinct species by editing the genomes of living relatives, and to spin out conservation technology from that work.
The main international transhumanist membership organization, founded in 1998 as the World Transhumanist Association and now largely dormant as an institution.
A biotechnology company developing drugs to extend healthy lifespan in dogs, working through the veterinary regulator that will consider lifespan itself as an indication.
A Virginia nonprofit founded in the early 2000s that used prize competitions to seed research on life extension, regenerative medicine and organ engineering.
American neurotechnology company founded in 2016 developing a wireless implanted brain–computer interface with flexible electrode threads inserted by a surgical robot.
A biotechnology company founded in 2021 to screen transcription-factor combinations that restore youthful function to aged cells without changing their identity.
A longevity biotechnology company funded by Sam Altman with the stated goal of adding ten years of healthy life, working on autophagy, reprogramming and plasma-inspired therapies.
A California nonprofit founded in 2009 to fund rejuvenation research organized around seven categories of accumulated cellular damage, renamed Lifespan Research Institute in 2024.
A neurotechnology company developing an endovascular brain–computer interface implanted through a blood vessel rather than by opening the skull.
A $101 million incentive competition launched in 2023 that rewards a therapy restoring at least a decade of muscle, cognitive and immune function in older adults.